-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $18

Benzinga·08/13/2025 12:34:39
Listen to the news
B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $20 to $18.